Brivaracetam Differentially Affects Voltage-Gated Sodium Currents Without Impairing Sustained Repetitive Firing in Neurons

CNS Neuroscience and Therapeutics

Volumn 21, Issue 3, 2015, Pages 241-251

  Niespodziany, Isabelle ^a   André, Véronique Marie ^a   Leclère, Nathalie ^a   Hanon, Etienne ^a   Ghisdal, Philippe ^a   Wolff, Christian ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Action potential firing; Antiepileptic drug; Neurons; Voltage gated sodium channel

Indexed keywords

BRIVARACETAM; CARBAMAZEPINE; VOLTAGE GATED SODIUM CHANNEL; ANTICONVULSIVE AGENT; VOLTAGE GATED SODIUM CHANNEL BLOCKING AGENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN CELL; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFICACY; HIPPOCAMPAL CA1 REGION; MALE; MOUSE; NERVE CELL; NEUROBLASTOMA CELL; NONHUMAN; PYRAMIDAL NERVE CELL; RAT; ANIMAL; BRAIN CORTEX; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; MEMBRANE POTENTIAL; METABOLISM; PATCH CLAMP TECHNIQUE; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; TISSUE CULTURE TECHNIQUE; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; ANTICONVULSANTS; CA1 REGION, HIPPOCAMPAL; CARBAMAZEPINE; CELL LINE, TUMOR; CELLS, CULTURED; CEREBRAL CORTEX; CLINICAL TRIALS, PHASE III AS TOPIC; MALE; MEMBRANE POTENTIALS; MICE; MICE, INBRED C57BL; NEURONS; PATCH-CLAMP TECHNIQUES; RATS, WISTAR; TISSUE CULTURE TECHNIQUES; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS; VOLTAGE-GATED SODIUM CHANNELS;

EID: 84923946321     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12347     Document Type: Article

References (39)

1. Kasteleijn-Nolst Trenite DG, Genton P, Parain D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 2007;69:1027-1034.
2. Malawska B, Kulig K. Brivaracetam: A new drug in development for epilepsy and neuropathic pain. Expert Opin Investig Drugs 2008;17:361-369.
3. Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial. Epilepsia 2013;54:89-97.
4. Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014;55:38-46.
5. Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014;55:47-56.
6. Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014;55:57-66.
7. Rogawski MA. Brivaracetam: A rational drug discovery success story. Br J Pharmacol 2008;154:1555-1557.
8. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101:9861-9866.
9. Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties. Eur J Pharmacol 2011;664:36-44.
10. Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008;154:1662-1671.
11. Sargentini-Maier ML, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol 2007;63:680-688.
12. Yang XF, Weisenfeld A, Rothman SM. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 2007;48:1861-1869.
13. Meehan AL, Yang X, McAdams BD, Yuan L, Rothman SM. A new mechanism for antiepileptic drug action: Vesicular entry may mediate the effects of levetiracetam. J Neurophysiol 2011;106:1227-1239.
14. Klitgaard H, Verdru P. Levetiracetam: The first SV2A ligand for the treatment of epilepsy. Expert Opin Drug Discov 2007;2:1537-1545.
15. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001;306:5-8.
16. Vogl C, Mochida S, Wolff C, Whalley BJ, Stephens GJ. The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca2+ channels through an intracellular pathway. Mol Pharmacol 2012;82:199-208.
17. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002;136:659-672.
18. Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001;10:279-286.
19. Zona C, Pieri M, Carunchio I, Curcio L, Klitgaard H, Margineanu DG. Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. Epilepsy Res 2010;88:46-54.
20. Matsuki N, Quandt FN, Ten Eick RE, Yeh JZ. Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells. J Pharmacol Exp Ther 1984;228:523-530.
21. Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol Pharmacol 1985;27:549-558.
22. Niespodziany I, Klitgaard H, Margineanu DG. Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices. NeuroReport 2003;14:1273-1276.
23. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553-564.
24. Niespodziany I, Leclere N, Vandenplas C, Foerch P, Wolff C. Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation. J Neurosci Res 2013;91:436-443.
25. Niespodziany I, Leclère N, Matagne A, Wolff C. Brivaracetam modulates Na currents expressed in a neuroblastoma cell line: Comparison with carbamazepine. Epilepsia 2009;50(Suppl. 11):107. Abstract Number 1.217.
26. Bonifacio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-da-Silva P. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: Comparison with carbamazepine. Epilepsia 2001;42:600-608.
27. Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008;73:157-169.
28. Quandt FN. Modification of slow inactivation of single sodium channels by phenytoin in neuroblastoma cells. Mol Pharmacol 1988;34:557-565.
29. Zona C, Siniscalchi A, Mercuri NB, Bernardi G. Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience 1998;85:931-938.
30. Hill AJ, Jones NA, Smith I, et al. Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se. Neurosci Lett 2014;566:269-274.
31. Calabresi P, Centonze D, Marfia GA, Pisani A, Bernardi G. An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. Br J Pharmacol 1999;126:689-696.
32. DeLorenzo RJ, Sombati S, Coulter DA. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 2000;41(Suppl 1):S40-S44.
33. Deshpande LS, Nagarkatti N, Sombati S, DeLorenzo RJ. The novel antiepileptic drug carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure discharges and blocking sustained repetitive firing in cultured hippocampal neurons. Epilepsy Res 2008;79:158-165.
34. McLean MJ, Macdonald RL. Carbamazepine and 10, 11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986;238:727-738.
35. White HS, Wolf HH, Swinyard EA, Skeen GA, Sofia RD. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 1992;33:564-572.
36. Mendoza-Torreblanca JG, Vanoye-Carlo A, Phillips-Farfan BV, Carmona-Aparicio L, Gomez-Lira G. Synaptic vesicle protein 2A: Basic facts and role in synaptic function. Eur J Neurosci 2013;38:3529-3539.
37. Nowack A, Malarkey EB, Yao J, Bleckert A, Hill J, Bajjalieh SM. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. PLoS One 2011;6:e29560.
38. Yang X, Rothman SM, Dubinsky J. Brivaracetam is superior to levetiracetam in decreasing excitatory synaptic transmission. Epilepsia 2013;1:207. Abstract.
39. Margineanu DG, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 2000;42:281-285.